Purpose of Review <p>To review anti-obesity pharmacotherapy options and data to guide use in liver and kidney transplant recipients.</p> Recent Findings <p>The number of liver and kidney transplant recipients with obesity (BMI <i>≥</i> 30&#xa0;kg/m²) and concurrent disorders continues to grow. Up to 40% of liver and 33% of kidney recipients have obesity at transplant. Post-transplant weight gain is multi-factorial and common. Additionally, obesity and weight gain lead to lower allograft survival, increased cardiovascular risk, and decreased patient survival. Despite the high-risk population, anti-obesity medication use has not been widely studied or used in transplant recipients. Nutrient-stimulated hormones (NuSH) medications (glucagon-like peptide-1 receptor [GLP-1] agonists and dual agonists (GLP-1 and glucose-dependent insulinotropic polypeptide [GIP] receptor agonists) are highly effective agents for obesity treatment and cardiovascular event risk reduction in the general population and have spurred interest in obesity management in the transplant community. </p> Summary <p>Data from randomized, placebo-controlled trials and integration of obesity medication expertise into routine care for transplant recipients is key to ensure improvement in long-term graft and patient survival.</p>